Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

Benha University

Status: Invitation-only

Conditions: Cardiorenal Syndrome Type 1

Treatments: Drug: frusemide

Study type: Interventional

Funder types: Other

Identifiers

NCT06786728

MD8.1.2024

Details and patient eligibility

About

the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?

Enrollment: 146 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• • Patients of both genders aged 18-65 years old.

  • Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.)
  • Patients with Modified lung ultrasound score(LUSS) more than 15.

Exclusion criteria

• • Refusal to participate.

  • Patients with renal transplantation.
  • Unknowing baseline creatinine.
  • Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment,
  • RRT before recruitment,
  • known prehospitalization advanced chronic kidney disease (defined by an estimated GFR <30 mL/min/1.73 m2 or chronic RRT),
  • use of extracorporeal membrane oxygenation (ECMO),
  • diagnosis of hepatic cirrhosis or other condition with portal hypertension
  • Or postrenal causes of AKI

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

146 participants in 2 patient groups

the VEXUS group :in this group we use the vexus score to guide decongestive theapy

Active Comparator group

Description:

the use of diuretic if vexus score more than 1 at time of enrollement

Treatment:

Drug: frusemide

the lung US group : we use lung ultrasound score to detect degree of pulmonary congestion

Active Comparator group

Description:

if lung ultrasound score more than 15 we will start diuretic therapy

Treatment:

Drug: frusemide